Intravenous drug users can achieve a high sustained virological response rate: Experience from Croatian Reference Center for Viral Hepatitis

Hepatitis Monthly

Volumn 11, Issue 12, 2011, Pages 986-992

  Kurelac, Ivan ^a   Papic, Neven ^a   Sakoman, Slavko ^b   Orban, Mirjana ^b   Dusek, Davorka ^a   Coric, Marijana ^c   Vince, Adriana ^a  

^a Croatia   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c KBC Zagreb   (Croatia)

Author keywords

Addictive; Behavior; Chronic; Hepatitis; Hepatitis C; Infusions; Injections; Intravenous

Indexed keywords

BUPRENORPHINE; METHADONE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGE DISTRIBUTION; ANEMIA; ANXIETY; ARTICLE; CONTROLLED STUDY; CROATIA; DEPRESSION; DERMATITIS; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENETIC VARIABILITY; HEADACHE; HEPATITIS C; HUMAN; INSOMNIA; INTRAVENOUS DRUG ABUSE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUTROPENIA; PATIENT COMPLIANCE; PRURITUS; RASH; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VIROLOGY;

EID: 84855795874     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/kowsar.1735143X.779     Document Type: Article

References (28)

1. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis. 2010;202(7):984-90.
2. Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Vlahov D, et al. Changes in blood-borne infection risk among injection drug users. J Infect Dis. 2011;203(5):587-94.
3. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology. 1993;18(6):1338-43.
4. European Monitoring Centre for Drugs and Drug Addiction (eMCDDA). 2010 Annual report on the state of the drugs problem in Europe. Lisbon; 2010; Available from: http://www.emcdda.europa.eu/publications/annual-report/2010.
5. Mathei C, Buntinx F, van Damme P. Seroprevalence of hepatitis C markers among intravenous drug users in western european countries: a systematic review. J Viral Hepat. 2002;9(3):157-73.
6. Reimer J, Lorenzen J, Baetz B, Fischer B, Rehm J, Haasen C, et al. Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol. 2007;22(1):80-5.
7. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-93.
8. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138(1):108-15.
9. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 1997;26(3 Suppl 1):2S-10S.
10. Gazdag G, Horvath G, Szabo O, Ungvari GS. Barriers to antiviral treatment in hepatitis C infected intravenous drug users. Neuropsychopharmacol Hung. 2010;12(4):459-62.
11. Grebely J, Petoumenos K, Matthews GV, Haber P, Marks P, Lloyd AR, et al. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug Alcohol Depend. 2010;107(2-3):244-9.
12. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49(4):561-73.
13. Schaefer M, Mauss S. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Curr Drug Abuse Rev. 2008;1(2):177-87.
14. Belfiori B, Ciliegi P, Chiodera A, Bacosi D, Tosti A, Baldelli F, et al. Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Dig Liver Dis. 2009;41(4):303-7.
15. Zanini B, Covolo L, Donato F, Lanzini A. effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. Clin Ther. 2010;32(13):2139-59.
16. Kolaric B, Stajduhar D, Gajnik D, Rukavina T, Wiessing L. Serop-revalence of blood-borne infections and population sizes estimates in a population of injecting drug users in Croatia. Cent Eur J Public Health. 2010;18(2):104-9.
17. Medic A, Dzelalija B, Sonicki Z, Zekanovic D. Characteristics of hepatitis C infection in injecting drug users in Zadar County, Croatia. Coll Antropol. 2008;32(3):697-702.
18. Sakoman S. Prevention and treatment of hepatitis C in illicit drug users. Acta Med Croatica. 2009;63(5):437-42.
19. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696-9.
20. World Health organiation. Hepatitis C. Fact sheet n°164. Geneva: WHo; 1999 [updated 2011 June]; Available from: http://www.who.int/entity/mediacentre/factsheets/fs164/en/.
21. Manolakopoulos S, Deutsch MJ, Anagnostou O, Karatapanis S, Tiniakou E, papatheodoridis GV, et al. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int. 2010;30(10):1454-60.
22. del olmo JA, Ornia E, Serra MA, Garcia-Torres ML, Escudero A, Rodriguez F, et al. Changing prevalence, clinical features, and outcome of acute hepatitis in Spain (1982-2003). J Gastroenterol Hepatol. 2006;21(6):982-7.
23. Wasley A, Alter MJ. epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20(1):1-16.
24. Vince A, Iscic-Bes J, Zidovec Lepej S, Baca-Vrakela I, Bradaric N, Kurelac I, et al. Distribution of hepatitis C virus genotypes in Croatia--a 10 year retrospective study of four geographic regions. Coll Antropol. 2006;30(Suppl 2):139-43.
25. Bourliere M, Barberin JM, Rotily M, Guagliardo V, portal I, Lecomte L, et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat. 2002;9(1):62-70.
26. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007;19(9):741-7.
27. Zaller ND, Bazazi AR, Velazquez L, Rich JD. Attitudes toward methadone among out-of-treatment minority injection drug users: implications for health disparities. Int J Environ Res Public Health. 2009;6(2):787-97.
28. Litwin AH, Harris KA, Jr., Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat. 2009;37(1):32-40.